
THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 932 Session of
2017

INTRODUCED BY DiGIROLAMO, MURT, DRISCOLL, D. COSTA, PASHINSKI,
TAYLOR, D. MILLER, DOWLING, DAVIS, McNEILL, A. HARRIS, DeLUCA
AND CALTAGIRONE, MARCH 23, 2017

REFERRED TO COMMITTEE ON HUMAN SERVICES, MARCH 23, 2017

AN ACT

1 Providing for licensure of buprenorphine office-based
2 prescribers; limiting the use of buprenorphine; and
3 establishing penalties.

4 The General Assembly of the Commonwealth of Pennsylvania
5 hereby enacts as follows:

6 Section 1. Short title.

7 This act shall be known and may be cited as the Buprenorphine
8 Medically Assisted Treatment Act.

9 Section 2. Definitions.

10 The following words and phrases when used in this act shall
11 have the meanings given to them in this section unless the
12 context clearly indicates otherwise:

13 "Buprenorphine." A material, compound, mixture of
14 preparation containing buprenorphine or its salts used as
15 medically assisted treatment for opioid addiction.

16 "Buprenorphine office-based prescriber." A person that is
17 assigned a waiver from the Drug Enforcement Administration,
18 including a special identification number, commonly referred to

1 as the "X" DEA number, and provides office-based prescribing of
2 buprenorphine.

3 "Department." The Department of Drug and Alcohol Programs of
4 the Commonwealth.

5 Section 3. Buprenorphine Medically Assisted Treatment.

6 (a) Licensure.--The department shall establish a program for
7 licensure of buprenorphine office-based prescribers as qualified
8 by training and experience to prescribe buprenorphine.

9 (b) Fee.--A buprenorphine office-based prescriber shall pay
10 a fee of \$10,000 for licensure by the department.

11 (c) Prohibition.--No buprenorphine office-based prescriber
12 shall prescribe buprenorphine to a patient unless all of the
13 following occur:

14 (1) The patient provides evidence demonstrating active
15 participation in an addiction treatment program licensed by
16 the department.

17 (2) The evidence of participation in the addiction
18 treatment program is documented in the patient's medical
19 record.

20 (3) The buprenorphine office-based prescriber is
21 licensed by the department as provided under subsection (a).

22 (d) Violations.--The State Board of Medicine shall
23 promulgate guidelines providing specific periods of license
24 suspension or revocation for a buprenorphine office-based
25 prescriber who dispenses or prescribes buprenorphine in
26 violation of this act.

27 Section 4. Effective date.

28 This act shall take effect in 60 days.